Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

Oppenheimer reiterated a "buy" rating and set a $35.00 target price on shares of Inovio Pharmaceuticals in a research note on Friday, July 2nd. Jefferies Financial Group initiated coverage on Inovio Pharmaceuticals in a research note on Thursday, June 24th. They set a "hold" rating and a $9.00 price objective on the stock. Zacks Investment Research cut Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, August 13th.

Ino was downgraded by investment analysts at Bank of America from a "neutral" rating to an "underperform" rating in a research note issued to investors on Sept 10th. They presently have a $8.00 target price, down from their prior target price of $9.00.

Inovio downgraded to Underperform from Neutral at BofA BofA analyst Geoff Meacham downgraded Inovio to Underperform from Neutral with a price target of $8, down from $9. Meacham continues to see limited opportunity from the COVID-19 asset, for which he believes there is still meaningful value being reflected in the share price, the analyst tells investors in a research note.

Read more at:
https://thefly.com/n.php?id=3370280

Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company's stock. Inovio Pharmaceuticals currently has a consensus rating of "Hold" and an average target price of $14.13.